CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

EyeMarker Systems

EyeMarker Systems is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chalmers and Kubeck North

Chalmers and Kubeck North is a Salem, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AN2 Therapeutics

AN2 Therapeutics is a biopharmaceutical company that develops therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.

Nanōmix

Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.

Degraft-Johnson and Associates

Degraft-Johnson and Associates is a Chadds Ford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.